Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma

Susan Aherne; Mark Donnelly; Éanna J Ryan; Matthew G Davey; Ben Creavin; Erinn McGrath; Aoife McCarthy; Robert Geraghty; David Gibbons; Iris Nagtegaal; Alessandro Lugli; Richard Kirsch; Sean T Martin; Desmond C Winter; Kieran Sheahan; collaborators at the Centre for Colorectal Disease and International Tumour Budding Consortium funded by the Dutch Cancer Society

doi:10.1111/his.15192

Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma

Histopathology. 2024 Apr 17. doi: 10.1111/his.15192. Online ahead of print.

Authors

Susan Aherne^#^{1

2

3}, Mark Donnelly^{1

2}, Éanna J Ryan^#^{1

2}, Matthew G Davey¹, Ben Creavin^{1

2}, Erinn McGrath^{1

2}, Aoife McCarthy¹, Robert Geraghty¹, David Gibbons^{1

2

3}, Iris Nagtegaal³, Alessandro Lugli³, Richard Kirsch³, Sean T Martin^{1

2}, Desmond C Winter^{1

2}, Kieran Sheahan^{1

2

3}; collaborators at the Centre for Colorectal Disease and International Tumour Budding Consortium funded by the Dutch Cancer Society

Collaborators

collaborators at the Centre for Colorectal Disease and International Tumour Budding Consortium funded by the Dutch Cancer Society:
Ann Hanly, Rory Kennelly, David Fennelly, J Armstrong, G McVey, Ray Mc Dermott, G Doherty, H Dawson, I Nagtegaal, I Zlobec

Affiliations

¹ Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland.
² School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.
³ International Tumour Budding Consortium Funded by the Dutch Cancer Society, Amsterdam, The Netherlands.

^# Contributed equally.

PMID: 38629323
DOI: 10.1111/his.15192

Abstract

Background: Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility of TB assessment in the setting of neoadjuvant treatment.

Methods and results: A single-centre, retrospective cohort study was conducted. TB was assessed using the hot-spot International Tumour Budding Consortium (ITBCC) method and classified by the revised ITBCC criteria. Haematoxylin and eosin (H&E) and AE1/AE3 cytokeratin (CK) stains for ITB (intratumoural budding) in biopsies with PTB (peritumoural budding) and ITB (intratumoural budding) in resection specimens were compared. Logistic regression assessed budding as predictors of lymph node metastasis (LNM). Cox regression and Kaplan-Meier analyses investigated their utility as a predictor of disease-free (DFS) and overall (OS) survival. A total of 146 patients were included; 91 were male (62.3%). Thirty-seven cases (25.3%) had ITB on H&E and 79 (54.1%) had ITB on CK assessment of biopsy tissue. In univariable analysis, H&E ITB [odds (OR) = 2.709, 95% confidence interval (CI) = 1.261-5.822, P = 0.011] and CK ITB (OR = 2.165, 95% CI = 1.076-4.357, P = 0.030) predicted LNM. Biopsy-assessed H&E ITB (OR = 2.749, 95% CI = 1.258-6.528, P = 0.022) was an independent predictor of LNM. In Kaplan-Meier analysis, ITB identified on biopsy was associated with worse OS (H&E, P = 0.003, CK: P = 0.009) and DFS (H&E, P = 0.012; CK, P = 0.045). In resection specimens, CK PTB was associated with worse OS (P = 0.047), and both CK PTB and ITB with worse DFS (PTB, P = 0.014; ITB: P = 0.019). In multivariable analysis H&E ITB predicted OS (HR = 2.930, 95% CI = 1.261-6.809) and DFS (HR = 2.072, 95% CI = 1.031-4.164). CK PTB grading on resection also independently predicted OS (HR = 3.417, 95% CI = 1.45-8.053, P = 0.005).

Conclusion: Assessment of TB using H&E and CK may be feasible in rectal cancer biopsy and post-neoadjuvant therapy-treated resection specimens and is associated with LNM and worse survival outcomes. Future management strategies for rectal cancer might be tailored to incorporate these findings.

Keywords: neoadjuvant therapies; personalised medicine; rectal cancer; surgical pathology; tumour budding.

Abstract

Grants and funding